Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04836182 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction | PHASE2 | COMPLETED | 72 | — | — | Jun 8, 2021 | Jan 11, 2023 | Sep 11, 2023 | 19 | United States, Hungary +1 |
| Arm | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | EXPERIMENTAL | IONIS-AGT-LRX by subcutaneous injection once-weekly |
| Placebo | PLACEBO_COMPARATOR | Matching placebo by subcutaneous injection once-weekly |
| Name | Type | Description |
|---|---|---|
| IONIS-AGT-LRx | DRUG | Multiple doses of IONIS-AGT-LRx will be administered by SC injection. |
| Placebo | DRUG | IONIS-AGT-LRx-matching placebo will be administered by SC injection. |
Inclusion Criteria: 1. Females must be non-pregnant and non-lactating and of non- childbearing potential. 2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she must be willing to use a highly effective contraceptive...